Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Hinübergehen
Renz M. Hinübergehen - Was beim Sterben geshieht. Annäherungen an letzte Wahrheiten unseres Lebens. Freiburg i.Br.: Kreuz, 2013.
01.01.2013Hinübergehen
01.01.2013Kreuz
Renz Monika
Mystik, Liebe und Leidenschaft
Renz M. Mystik, Liebe und Leidenschaft - Geistliche Begleitung bei Dorothee Sölle. In: Geistliche Begleitung in evangelischer Perspektive: Modelle und Personen der Kirchengeschichte. Leipzig: Evangelische Verlagsanstalt, 2013. S. 364-372.
01.01.2013Mystik, Liebe und Leidenschaft
01.01.2013Evangelische Verlagsanstalt
Renz Monika
Leiden?
Renz M. Leiden? - Sich zum Leid verhalten. NOVA. Das Fachmagazin für Pflege und Betreuung 2013; 2013:12-13.
01.01.2013Leiden?
01.01.2013NOVA. Das Fachmagazin für Pflege und Betreuung 2013; 2013:12-13
Renz Monika
Multidisciplinary care in patients with prostate cancer: room for improvement
Strebel R, Winterhalder R, Morant R, Pless M, U H, Fehr M, Gillessen S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 2013; 21:2327-33.
01.01.2013Multidisciplinary care in patients with prostate cancer: room for improvement
01.01.2013Support Care Cancer 2013; 21:2327-33
Strebel RT, Winterhalder R, Morant R, Pless M, U Huber, Fehr Martin, Gillessen S, Schmid Hans-Peter, Sulser T, Cathomas R
Reply to: Population-Based Analysis of 4113 Patients With Acute Cholecystitis: Defining the Optimal Time Point for Laparoscopic Cholecystectomy
Banz V, Gsponer T, Candinas D, Gueller U. Reply to: Population-Based Analysis of 4113 Patients With Acute Cholecystitis: Defining the Optimal Time Point for Laparoscopic Cholecystectomy. Ann Surg 2012
14.12.2012Reply to: Population-Based Analysis of 4113 Patients With Acute Cholecystitis: Defining the Optimal Time Point for Laparoscopic Cholecystectomy
14.12.2012Ann Surg 2012
Banz Vanessa, Gsponer Thomas, Candinas Daniel, Gueller Ulrich
2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
Gillessen Sommer S, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch J, Horwich A, Zucali P, Gross-Goupil M, Bachner M, Oechsle K. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23:59-64.
13.12.20122-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial
13.12.2012Ann Oncol 2012; 23:59-64
Gillessen Sommer Silke, Fléchon A, Stoiber F, Kollmansberger C, Germa-Lluch JR, Horwich A, Zucali PA, Gross-Goupil M, Bachner M, Oechsle K
Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging?
Meiers P, Cil T, Gueller U, Zuber M. Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging?. Langenbecks Arch Surg 2012; 398:687-90.
11.12.2012Sentinel lymph node biopsy in early-stage breast cancer patients: improved survival through better staging?
11.12.2012Langenbecks Arch Surg 2012; 398:687-90
Meiers Pamela, Cil Tulin, Gueller Ulrich, Zuber Markus
TAPP or TEP? Population-based analysis of prospective data on 4,552 patients undergoing endoscopic inguinal hernia repair
Gass M, Banz V, Rosella L, Adamina M, Candinas D, Gueller U. TAPP or TEP? Population-based analysis of prospective data on 4,552 patients undergoing endoscopic inguinal hernia repair. World J Surg 2012; 36:2782-6.
01.12.2012TAPP or TEP? Population-based analysis of prospective data on 4,552 patients undergoing endoscopic inguinal hernia repair
01.12.2012World J Surg 2012; 36:2782-6
Gass Markus, Banz Vanessa M, Rosella Laura, Adamina Michel, Candinas Daniel, Gueller Ulrich
Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides
Held S, Brossart P, Driessen C, Schild H, Kurts C, Bringmann A, von Schwarzenberg K, Rückrich T, Tenzer S, Duchardt K, Heine A. Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides. Cancer Immunol Immunother 2012; 62:715-26.
25.11.2012Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides
25.11.2012Cancer Immunol Immunother 2012; 62:715-26
Held Stefanie Andrea Erika, Brossart Peter, Driessen Christoph, Schild Hansjörg, Kurts Christian, Bringmann Anita, von Schwarzenberg Karin, Rückrich Thomas, Tenzer Stefan, Duchardt Katharina Maria, Heine Annkristin
Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol 2012; 69:95-101.
22.11.2012Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas
22.11.2012Eur Neurol 2012; 69:95-101
Seystahl Katharina, Wiestler Benedikt, Hundsberger Thomas, Happold Caroline, Wick Wolfgang, Weller Michael, Wick Antje
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis
Oberholzer R, Hopkinson J, Baumann K, Omlin A, Kaasa S, Fearon K, Strasser F. Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage 2012; 46:77-95.
15.11.2012Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis
15.11.2012J Pain Symptom Manage 2012; 46:77-95
Oberholzer Rolf, Hopkinson Jane B, Baumann Kim, Omlin Aurelius, Kaasa Stein, Fearon Kenneth C, Strasser Florian
Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl S, Froehlich T, Largiader C, Joerger M. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol 2012; 71:361-70.
09.11.2012Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
09.11.2012Cancer Chemother Pharmacol 2012; 71:361-70
Mueller F, Büchel B, Köberle D, Schürch S, Pfister B, Krähenbühl St, Froehlich T K, Largiader C R, Joerger M
Unilateral myokymia of the tongue – two cases, different aetiologies
Leupold D, Felbecker A, Tettenborn B, Hundsberger T (2012). Unilateral myokymia of the tongue – two cases, different aetiologies.
08.11.2012Unilateral myokymia of the tongue – two cases, different aetiologies
08.11.2012SNG Tagung
Leupold Daniela, Felbecker Ansgar, Tettenborn Barbara, Hundsberger Thomas
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
Helbling D, Bougel S, Leibundgut E, Benhattar J, Yan P, Baertschi D, Borner M, Widmer L, Saletti P, Rauch D, Madlung A, Winterhalder R, Burkhard R, Gloor B, Bosman F, Sun H, Gautschi O, Bodoky G, Köberle D. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2012; 24:718-25.
08.11.2012Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
08.11.2012Ann Oncol 2012; 24:718-25
Helbling D, Bougel S, Leibundgut E O, Benhattar J, Yan P, Baertschi D, Borner M, Widmer L, Saletti P, Rauch D, Madlung A, Winterhalder R, Burkhard R, Gloor B, Bosman F, Sun H, Gautschi O, Bodoky G, Köberle Dieter
Thrombophilidiagnostik - Entscheidungshilfe in komplexen Risikosituationen
Baumann M, Korte W. Thrombophilidiagnostik - Entscheidungshilfe in komplexen Risikosituationen. Cardiovasc 2012; 6:4-6.
01.11.2012Thrombophilidiagnostik - Entscheidungshilfe in komplexen Risikosituationen
01.11.2012Cardiovasc 2012; 6:4-6
Baumann Michael, Korte Wolfgang
Treatment concepts of oral cancer.
Bredell M, Rordorf T, Studer G. Treatment concepts of oral cancer. SADJ 2012; 67:574-6.
01.11.2012Treatment concepts of oral cancer.
01.11.2012SADJ 2012; 67:574-6
Bredell M G, Rordorf Tamara, Studer G
Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial.
Bucher C, Lehmann T, Tichelli A, Tzankov A, Dirnhofer S, Passweg J, Rovó A. Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial. J Clin Pathol 2012; 66:24-8.
26.10.2012Comparison of a powered bone marrow biopsy device with a manual system: results of a prospective randomised controlled trial.
26.10.2012J Clin Pathol 2012; 66:24-8
Bucher Christoph, Lehmann Thomas, Tichelli André, Tzankov Alexander, Dirnhofer Stephan, Passweg Jakob, Rovó Alicia
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel R, Dueck A, Geyer H, Kiladjian J, Slot S, Zweegman S, te Boekhorst P, Commandeur S, Schouten H, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl H, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto J, Ranta D, Roy L, Cahn J, Harrison C, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson P, Barbui T, Barosi G, Vannucchi A, Passamonti F, Andreasson B, Ferrari M, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa R. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 2012; 30:4098-103.
15.10.2012Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
15.10.2012J Clin Oncol 2012; 30:4098-103
Emanuel Robyn M, Dueck Amylou C, Geyer Holly L, Kiladjian Jean-Jacques, Slot Stefanie, Zweegman Sonja, te Boekhorst Peter A W, Commandeur Suzan, Schouten Harry, Sackmann Federico, Kerguelen Fuentes Ana, Hernández-Maraver Dolores, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Doehner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L, Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M, Passamonti Francesco, Andreasson Bjorn, Ferrari Maria L, Rambaldi Alessandro, Samuelsson Jan, Birgegard Gunnar, Tefferi Ayalew, Mesa Ruben A
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
Gallerani E, D'Incalci M, Sala F, Cereda R, Marsoni S, de Braud F, Driessen C, Böhm S, Martinelli G, Delmonte A, Hess U, Noberasco C, Marangon E, Brunelli D, Zucchetti M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. Eur J Cancer 2012; 49:290-6.
08.10.2012A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma
08.10.2012Eur J Cancer 2012; 49:290-6
Gallerani Elisa, D'Incalci Maurizio, Sala Federica, Cereda Roberta, Marsoni Silvia, de Braud Filippo, Driessen Christoph, Böhm Steffen, Martinelli Giovanni, Delmonte Angelo, Hess Urs, Noberasco Cristina, Marangon Elena, Brunelli Dario, Zucchetti Massimo, Sessa Cristiana
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
08.10.2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
08.10.2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T